You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《即日市評》恆指向下 友邦走弱 藥明系及理想捱沽
恆指今日反覆向下。美股科技股造好,道指及納指隔晚各升0.2%及0.8%,日本央行宣布結束負利率及孳息率曲線控制政策,17年來首次加息,將短期利率從負0.1%上調至0至0.1%範圍內,日本央行行長植田和男表示不太可能大幅加息,指通脹尚未達標,有必要保持寬鬆貨幣環境。執筆之時,美國10年期債券孳息率升至4.32厘,美匯指數升至103.94,道指期貨最新升12點或0.03%,納指期貨最新升0.03%。上證綜指全日跌22點或0.72%收3,062點,深證成指跌0.58%,而滬深兩市成交額共1.08萬億人民幣。 港股反覆下跌,恆指低開109點,初段跌245點一度低見16,492點,其後跌幅一度收窄至54點,全日跌207點或1.2%,收16,529點;國指跌67點或1.2%,收5,780點;恆生科技指數跌65點或1.8%,報3,528點。大市全日成交總額906.89億元,滬、深港通南下交易淨流入43.86億及42.37億元人民幣。 科網股偏軟,騰訊(00700.HK)股價跌1.7%收285元,美團(03690.HK)下滑1.3%,小米(01810.HK)走低0.5%。友邦(01299.HK)股價跌2.8%收57.4元。 【友邦股價弱 藥明系受壓】 醫藥股受壓,藥明康德(02359.HK)去年純利增21%,全日股價跌7.5%,同系藥明生物(02269.HK)跌5.7%。其他,金斯瑞(01548.HK)及信達生物(01801.HK)跌7%及8.3%。高盛發表報告指,藥明康德2023年第四季銷售額符合公司先前的指引。不過,面對美國《生物安全法案》的不確定性,藥明康德2024年收入指引略低於去年發布的早期管理指引,以及投資者的預期。因此將藥明康德的目標價下調至54.2元,維持「中性」評級。 【跌股千二隻 理想有沽壓】 港股今日市寬轉弱,主板股票的升跌比率為13比29(上日為24比19),下跌1,233股份隻(跌幅2.8%),恆指成份股今日12隻股份上升,67隻股份下跌,升跌比率為15比82(上日為50比46);大市今日錄沽空180.86億元,佔可沽空股份成交額798.55億元的22.649%(上日為19.186%)。 理想(02015.HK)新車「MEGA」據報訂單遜預期,管理層考慮下調銷售目標,理想股價下挫8%。零跑(09863.HK)及蔚來(09866.HK)跌7.7%及6.3%。內媒早前報道,理想對於MEGA在24小時內的預期訂單是3,000台左右,但最終僅實現目標的一半。MEGA發布半個月內亦只收到近4,000台的訂單,本月工廠MEGA的產能為5,000台。報道指,在發布前,理想內部對於MEGA的年銷售預期為7萬至8萬台。理想核心管理層正討論是否需要把銷售目標下調至5萬至6萬台,但最終數字尚未確定。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account